Hyundai Bioscience Co. Ltd
Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea.
Hyundai Bioscience Co. Ltd (048410) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.032x
Based on the latest financial reports, Hyundai Bioscience Co. Ltd (048410) has a cash flow conversion efficiency ratio of -0.032x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-3.51 Billion) by net assets (₩110.28 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hyundai Bioscience Co. Ltd - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Hyundai Bioscience Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Hyundai Bioscience Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hyundai Bioscience Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangdong Sky Dragon Printing Ink Group Co Ltd
SHE:300063
|
0.063x |
|
Craftsman Automation Limited
NSE:CRAFTSMAN
|
0.046x |
|
Univest Corporation Pennsylvania
NASDAQ:UVSP
|
0.034x |
|
Ratch Group Public Company Limited
BK:RATCH
|
0.054x |
|
Aptus Value Housing Finance India Limited
NSE:APTUS
|
-0.027x |
|
Medicover AB Series B
LSE:0RPS
|
0.118x |
|
Northern Data AG
PINK:NDTAF
|
-0.021x |
|
Alliance Material Co., Ltd.
TWO:3595
|
0.027x |
Annual Cash Flow Conversion Efficiency for Hyundai Bioscience Co. Ltd (2008–2024)
The table below shows the annual cash flow conversion efficiency of Hyundai Bioscience Co. Ltd from 2008 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩39.44 Billion | ₩2.26 Billion | 0.057x | +143.12% |
| 2023-12-31 | ₩45.27 Billion | ₩-6.01 Billion | -0.133x | +53.28% |
| 2022-12-31 | ₩58.24 Billion | ₩-16.54 Billion | -0.284x | -3148.24% |
| 2021-12-31 | ₩61.57 Billion | ₩-538.48 Million | -0.009x | -105.97% |
| 2020-12-31 | ₩51.22 Billion | ₩7.50 Billion | 0.146x | -25.02% |
| 2019-12-31 | ₩46.99 Billion | ₩9.18 Billion | 0.195x | +58.00% |
| 2018-12-31 | ₩40.48 Billion | ₩5.01 Billion | 0.124x | +203.33% |
| 2017-12-31 | ₩30.89 Billion | ₩-3.70 Billion | -0.120x | +49.76% |
| 2016-12-31 | ₩18.21 Billion | ₩-4.34 Billion | -0.238x | -6808.19% |
| 2015-12-31 | ₩24.60 Billion | ₩87.36 Million | 0.004x | -93.48% |
| 2014-12-31 | ₩22.49 Billion | ₩1.22 Billion | 0.054x | -80.56% |
| 2011-12-31 | ₩14.17 Billion | ₩3.97 Billion | 0.280x | +35.95% |
| 2008-12-31 | ₩50.36 Billion | ₩10.37 Billion | 0.206x | -- |